Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

128.16USD
19 Jun 2019
Change (% chg)

$7.52 (+6.23%)
Prev Close
$120.64
Open
$123.00
Day's High
$129.15
Day's Low
$122.85
Volume
1,295,398
Avg. Vol
573,945
52-wk High
$197.00
52-wk Low
$114.27

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

Financials

  AGN.N Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -11.66 -- --
ROI: -3.08 14.23 13.82
ROE: -5.61 15.46 15.24

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

18 Jun 2019

UPDATE 5-Pfizer makes $10.6 bln cancer bet in cash deal for Array Biopharma

June 17 Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

18 Jun 2019

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

29 May 2019

UPDATE 1-Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

28 May 2019

Allergan to recall textured breast implants in Canada

May 28 Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.

28 May 2019

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

28 May 2019

REFILE-UPDATE 1-Allergan's Vraylar wins U.S. FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

28 May 2019

Allergan's Vraylar wins FDA approval for bipolar depression

May 28 Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, making it a treatment option for a full spectrum of the condition's cyclical symptoms, the company said on Monday.

28 May 2019

Allergan CEO says company is urgently looking at all options to boost share price

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

07 May 2019

UPDATE 3-Allergan CEO says company is urgently looking at all options to boost share price

May 7 Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

07 May 2019

Earnings vs. Estimates